Fulgent Genetic (NASDAQ:FLGT) CFO Paul Kim sold 6,134 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $5.71, for a total transaction of $35,025.14. Following the completion of the sale, the chief financial officer now directly owns 388,602 shares of the company’s stock, valued at approximately $2,218,917.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Fulgent Genetic (NASDAQ FLGT) traded up 2.78% during mid-day trading on Monday, hitting $5.92. 10,235 shares of the company were exchanged. The firm’s market capitalization is $104.74 million. The company’s 50-day moving average price is $6.34 and its 200-day moving average price is $8.77. Fulgent Genetic has a 12-month low of $4.49 and a 12-month high of $13.90.

Fulgent Genetic (NASDAQ:FLGT) last released its quarterly earnings data on Monday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. The business had revenue of $4.64 million during the quarter, compared to analysts’ expectations of $5.03 million. Fulgent Genetic had a negative net margin of 0.42% and a negative return on equity of 0.02%. Equities research analysts predict that Fulgent Genetic will post $0.14 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Fulgent Genetic (NASDAQ:FLGT) CFO Sells $35,025.14 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/14/fulgent-genetic-nasdaqflgt-cfo-sells-35025-14-in-stock.html.

A number of institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its position in Fulgent Genetic by 2,046.0% in the first quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock worth $118,000 after buying an additional 10,230 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Fulgent Genetic during the first quarter valued at about $122,000. Blair William & Co. IL acquired a new position in shares of Fulgent Genetic during the first quarter valued at about $287,000. Scholtz & Company LLC boosted its position in shares of Fulgent Genetic by 50.3% in the first quarter. Scholtz & Company LLC now owns 266,705 shares of the company’s stock valued at $2,912,000 after buying an additional 89,205 shares during the period. Finally, William Blair Investment Management LLC boosted its position in shares of Fulgent Genetic by 10.4% in the second quarter. William Blair Investment Management LLC now owns 640,219 shares of the company’s stock valued at $4,091,000 after buying an additional 60,508 shares during the period. Institutional investors and hedge funds own 20.09% of the company’s stock.

A number of brokerages recently weighed in on FLGT. Zacks Investment Research raised shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, July 10th. Credit Suisse Group lowered their price target on shares of Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, August 8th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $7.00 price target (down previously from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th.

About Fulgent Genetic

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.